At the same time, we must also keep an open mind as it is clear that some tumours without these genetic abnormalities can be equally sensitive to PI3K inhibition, and recognize that the identification and validation of additional predictive biomarkers or signatures will be necessary. This evidence concerns the gene PIK3CA and neoplasm.